Parathyroid Disorders Market Overview
As per MRFR analysis, the Parathyroid Disorders Market Size was estimated at 1.88 (USD Billion) in 2023. The Parathyroid Disorders Market Industry is expected to grow from 1.99(USD Billion) in 2024 to 3.7 (USD Billion) by 2035. The Parathyroid Disorders Market CAGR (growth rate) is expected to be around 5.81% during the forecast period (2025-2035).
Key Parathyroid Disorders Market Trends Highlighted
The Global Parathyroid Disorders Market is experiencing significant growth driven by various key market drivers. An increase in the prevalence of parathyroid disorders, such as hyperparathyroidism, is primarily due to the aging population and lifestyle factors that promote these conditions. As healthcare providers expand their focus on early diagnosis and treatment options, the market is witnessing a steady rise in demand for effective therapies and surgical procedures. Advances in diagnostic technologies, including imaging and laboratory tests, have improved early detection rates, further driving the market forward. Emerging opportunities exist in the research and development of novel therapeutics and less invasive treatment options, which can enhance patient outcomes and compliance.
The shift towards personalized medicine presents another avenue for growth, as treatments tailored to individual patient profiles can significantly improve efficacy. Moreover, increasing awareness about parathyroid disorders and the importance of early intervention among both healthcare professionals and patients highlights the potential to capture a wider audience within the global healthcare landscape.
Trends in recent times indicate a rise in collaborations and partnerships among pharmaceutical companies, research institutions, and healthcare providers to foster innovation in treatment modalities. Additionally, there is a growing emphasis on telemedicine and remote monitoring, which can facilitate access to care for patients in underserved regions.
This shift towards more integrated care models reflects a broader trend in the healthcare industry, acknowledging the need for comprehensive approaches to managing parathyroid disorders effectively. Overall, the Global Parathyroid Disorders Market is positioned for robust growth as it adapts to meet evolving healthcare needs and leverages advancements in technology and treatment methodologies.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Parathyroid Disorders Market Drivers
Increasing Prevalence of Parathyroid Disorders
Globally, the prevalence of parathyroid diseases, including primary hyperparathyroidism, is increasing due to aging populations and changes in lifestyle. By 2050, there will likely be 1.5 billion persons over 65, according to the World Health Organization (WHO). This is usually accompanied by a rise in chronic illnesses, such as parathyroid problems. A greater number of patients will probably require parathyroid disease diagnosis and treatment as a result of the aging population.
At the same time, improvements in diagnostic techniques and increased knowledge of these conditions among medical professionals allow for earlier identification and therapy. Countries' healthcare systems, especially those in North America and Europe, are improving, which helps the global market for parathyroid disorders and opens up a lot of growth prospects for pharmaceutical companies and manufacturers of medical devices.
Advancements in Diagnostic and Treatment Technologies
Technological innovations and enhanced treatment options for parathyroid disorders significantly propel the Global Parathyroid Disorders Market Industry. For instance, multi-disciplinary approaches combining minimally invasive surgeries and novel pharmacological interventions have shown increased efficacy. According to recent guidelines published by organizations such as the American Association of Endocrine Surgeons, less invasive surgical techniques for parathyroidectomy are gaining traction, with reduced recovery times and complications.
This evolution in patient care translates into higher procedure volumes and increased demand for advanced diagnostic tools. Furthermore, with the rise of telemedicine and digital health solutions, healthcare accessibility and monitoring can be improved, especially in remote areas, thereby broadening patient reach and uplifting the market trajectory.
Increasing Funding for Research and Development
The Global Parathyroid Disorders Market Industry is being fueled by an increase in public and private sector funding for Research and Development (R) in endocrine disorders. Recent investments from government agencies and private institutions have spurred innovation in therapies and the management of parathyroid conditions. For example, the National Institutes of Health (NIH) has allocated substantial funds towards understanding the genetic underpinnings and potential treatment pathways for disorders such as hyperparathyroidism and multiple endocrine neoplasia.The result of such investment is a growing portfolio of clinical trials and novel interventions entering the marketplace, thereby likely increasing treatment availability and driving growth in the market overall.
Parathyroid Disorders Market Segment Insights
Parathyroid Disorders Market Type of Disorder Insights
The Global Parathyroid Disorders Market is experiencing notable growth, driven by an increasing prevalence of parathyroid disorders across various demographics. Focusing on the Type of Disorder segment, the market comprises Primary Hyperparathyroidism, Secondary Hyperparathyroidism, and Tertiary Hyperparathyroidism. In 2024, Primary Hyperparathyroidism is generated substantial revenue, amounting to 0.9 USD Billion, and is expected to rise to 1.6 USD Billion by 2035, reflecting a significant interest in diagnosing and treating this condition, which is characterized by excess parathyroid hormone leading to elevated calcium levels in patients.
This condition's majority holding in the market is largely due to its high incidence rates and the corresponding demand for effective therapeutic solutions. Secondary Hyperparathyroidism is anticipated to account for a revenue of 0.6 USD Billion in 2024, increasing to 1.1 USD Billion by 2035. This disorder typically arises from chronic kidney disease, amplifying the interest among healthcare professionals in identifying and treating this condition early on. The noteworthy growth in this area is largely influenced by rising kidney disease cases globally, propelling advancements in treatment methodologies and raising awareness about the significance of addressing secondary causes of hyperparathyroidism.
Tertiary Hyperparathyroidism, while smaller in market share, stands at a valuation of 0.49 USD Billion in 2024 and is expected to reach 1.0 USD Billion by 2035. The condition, often associated with prolonged secondary hyperparathyroidism, further underscores the importance of corrective measures in patients who have undergone kidney transplants or suffer from long-standing renal issues. Overall, significant trends influencing the Global Parathyroid Disorders Market segmentation are driven by the increasing incidence of these disorders, the necessity for effective treatment options, and ongoing research and development efforts aimed at better therapeutic strategies.With a critical focus on these types of disorders, stakeholders are well-positioned to capitalize on the growth opportunities within the market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Parathyroid Disorders Market Treatment Type Insights
The Global Parathyroid Disorders Market, valued at 1.99 Billion USD in 2024, encompasses a diverse range of treatment types essential for managing these disorders. The treatment modalities include Medications, Surgery, Radiation Therapy, and Observation, each playing a unique role in patient care. Medications are vital for patients requiring ongoing management of hormone levels, while Surgery is often preferred for addressing underlying issues directly by removing abnormal tissue. Radiation Therapy serves as an option for specific cases where traditional methods are less effective, and Observation is typically used for patients without significant symptoms.
As of 2035, the market is expected to expand significantly, reflecting the need for continued innovation and improved treatment outcomes. The drivers of this market growth include an aging population and an increased prevalence of parathyroid disorders. The Global Parathyroid Disorders Market statistics indicate a growing demand for effective and personalized treatment approaches, highlighting the importance of Surgery and Medications, which are critical in providing patients with comprehensive care. However, challenges such as high treatment costs and limited access to specialized care may impact market penetration and growth opportunities globally.
Parathyroid Disorders Market Diagnosis Method Insights
The Global Parathyroid Disorders Market is valued at 1.99 Billion USD in 2024, reflecting strong growth drivers in the Diagnosis Method segment. Diagnosis methods are crucial for detecting parathyroid disorders, which directly impact treatment decisions and patient outcomes. Blood tests play a pivotal role as they help measure calcium and parathyroid hormone levels, serving as primary indicators for diagnosis. Imaging tests are also significant; they assist in visualizing abnormalities in the parathyroid glands, enhancing the accuracy of assessments.Biopsies, while less common, provide definitive evidence for diagnosis, particularly in ambiguous cases.
As healthcare systems globally continue to prioritize accurate and timely diagnoses, advancements in technology and methodology are set to further enhance the capabilities of these diagnostic tools, ensuring the Global Parathyroid Disorders Market segmentation remains robust. Overall, the market growth for diagnosis methods is supported by increasing awareness and challenges related to parathyroid disorders worldwide.
Parathyroid Disorders Market Patient Age Group Insights
The Global Parathyroid Disorders Market, with a valuation of 1.99 USD Billion in 2024, is significantly influenced by the Patient Age Group segment, which comprises Children, Adults, and the Elderly. This marketplace is characterized by varying prevalence rates of parathyroid disorders across these age categories, where the elderly population, being at a higher risk for these disorders, plays a crucial role in market dynamics. As people age, the incidence of conditions such as hyperparathyroidism increases, driving demand for healthcare services and treatment options tailored to their specific needs.
Adults also represent a significant demographic, often facing challenges related to lifestyle diseases that can precipitate parathyroid issues. Meanwhile, Children, while less commonly affected, require specialized approaches and care, emphasizing the need for targeted treatment solutions in pediatrics.
The growing awareness and advancements in treatment methodologies present opportunities for expansion in this market. However, challenges such as the underdiagnosis of parathyroid disorders, especially among younger populations, persist and need addressing to enhance overall treatment outcomes.These factors collectively shape the Global Parathyroid Disorders Market segmentation, providing valuable insights into opportunities for growth and development across age-related profiles.
Parathyroid Disorders Market Regional Insights
The Regional segmentation of the Global Parathyroid Disorders Market indicates a robust growth trajectory across multiple regions, driven by the increasing prevalence of parathyroid disorders and advancements in treatment options. In 2024, North America leads the market with an impressive value of 0.9 USD Billion, projected to rise significantly to 1.7 USD Billion by 2035, making it a dominant player in the Global Parathyroid Disorders Market revenue landscape. Europe follows closely, with a market value of 0.6 USD Billion in 2024 and an expected growth to 1.1 USD Billion by 2035, showcasing strong advancements in healthcare infrastructure and increased awareness.
The APAC region, though currently smaller with a value of 0.25 USD Billion in 2024, is set for considerable growth to 0.55 USD Billion by 2035, driven by rising healthcare expenditures and a growing geriatric population. South America, projected at 0.1 USD Billion in 2024, is anticipated to gain traction, reaching 0.2 USD Billion by 2035, primarily due to improving access to healthcare. Meanwhile, the Middle East and Africa (MEA) market is valued at 0.14 USD Billion in 2024, growing to 0.25 USD Billion by 2035, reflecting significant investments in healthcare systems in the region.Overall, the Global Parathyroid Disorders Market data illustrates a promising landscape, with North America and Europe holding the majority share due to better healthcare access and innovative treatment methodologies.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Parathyroid Disorders Market Key Players and Competitive Insights
The Global Parathyroid Disorders Market is characterized by a competitive landscape that is continuously evolving due to advancements in medical research and a growing focus on targeted therapies. As parathyroid disorders become more prevalent, pharmaceutical companies are investing heavily in the development of innovative treatment options to address the specific needs of patients suffering from these conditions. Competition is marked by the entry of various players into the market; each aims to capture a share through unique offerings and strategic partnerships. The market is defined by the introduction of next-generation therapies, which promise improved efficacy and safety profiles.
As companies navigate regulatory landscapes and consumer demands, understanding competitive positioning and the unique value propositions of each player becomes crucial for maintaining market share and driving growth.AbbVie is recognized as a significant player in the Global Parathyroid Disorders Market, leveraging its extensive experience in biopharmaceuticals to deliver innovative treatments. Known for its strong research and development capabilities, AbbVie focuses on developing targeted therapies that tackle parathyroid disorders specifically.
The company's established presence in the global market is underscored by its commitment to patient-centric solutions and its robust pipeline that often features collaborations with academic institutions and other healthcare entities. AbbVie's strengths lie in its comprehensive understanding of the complex biology associated with parathyroid disorders, allowing it to position itself effectively within the competitive landscape.
The company's well-resourced infrastructure supports its ability to navigate regulatory challenges efficiently, lending further credibility to its claims of quality and innovation in its offerings.Eli Lilly has made notable strides in the Global Parathyroid Disorders Market through its diversified portfolio of key products aimed at treating various endocrine disorders, including those affecting the parathyroid gland. The company’s market presence is bolstered by its commitment to research and development, particularly in the field of hormone-related therapies.
Eli Lilly’s strengths are amplified by its strategic approach towards mergers and acquisitions, which has enabled it to enhance its product offerings and expand its technological capabilities in the global arena. The company continuously seeks to improve patient outcomes through innovative treatments that demonstrate both efficacy and safety. As part of its business strategy, Eli Lilly actively engages in collaborative partnerships, allowing it to tap into new markets and leverage expertise in parathyroid disorders, ultimately reinforcing its position as a key player in this specialized field.
Key Companies in the Parathyroid Disorders Market Include
- AbbVie
- Eli Lilly
- Zymeworks
- GSK
- Kyowa Hakko Kirin
- Teva Pharmaceutical Industries
- Novartis
- F. HoffmannLa Roche
- BristolMyers Squibb
- Merck and Co.
- Purdue Pharma
- Amgen
Parathyroid Disorders Market Industry Developments
The Global Parathyroid Disorders Market has seen notable developments recently, with increased investment in research and development from key players such as AbbVie, Eli Lilly, and Novartis, focusing on novel therapeutic approaches for conditions like hyperparathyroidism. In October 2023, GSK announced advancements in their parathyroid hormone candidates, contributing to the competitive landscape. The market is experiencing growth due to rising incidences of parathyroid disorders, influencing pharmaceutical companies to enhance their product portfolios. In September 2023, Teva Pharmaceutical Industries expanded its operations to include parathyroid disorder treatments and reported a significant growth in market valuation, further bolstering the competitive environment.
Additionally, there have been no major mergers or acquisitions reported in this sector involving the specified companies over the last few months, reflecting a period of stable development. Overall, the combination of increasing product advancements by companies such as F. Hoffmann-La Roche and Amgen, coupled with the growing awareness about parathyroid disorders, is shaping the global market landscape significantly.
Parathyroid Disorders Market Segmentation Insights
Parathyroid Disorders Market Type of Disorder Outlook
- Primary Hyperparathyroidism
- Secondary Hyperparathyroidism
- Tertiary Hyperparathyroidism
Parathyroid Disorders Market Treatment Type Outlook
- Medications
- Surgery
- Radiation Therapy
- Observation
Parathyroid Disorders Market Diagnosis Method Outlook
- Blood Tests
- Imaging Tests
- Biopsies
Parathyroid Disorders Market Patient Age Group Outlook
Parathyroid Disorders Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric Source: |
Details |
| MARKET SIZE 2023 |
1.88(USD Billion) |
| MARKET SIZE 2024 |
1.99(USD Billion) |
| MARKET SIZE 2035 |
3.7(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) |
5.81% (2025 - 2035) |
| REPORT COVERAGE |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR |
2024 |
| MARKET FORECAST PERIOD |
2025 - 2035 |
| HISTORICAL DATA |
2019 - 2024 |
| MARKET FORECAST UNITS |
USD Billion |
| KEY COMPANIES PROFILED |
AbbVie, Eli Lilly, Zymeworks, GSK, Kyowa Hakko Kirin, Teva Pharmaceutical Industries, Novartis, F. HoffmannLa Roche, BristolMyers Squibb, Merck and Co., Purdue Pharma, Amgen |
| SEGMENTS COVERED |
Type of Disorder, Treatment Type, Diagnosis Method, Patient Age Group, Regional |
| KEY MARKET OPPORTUNITIES |
Growing elderly population, Increasing prevalence of diabetes, Advancements in diagnostic technologies, Rising demand for personalized medicine, Enhanced treatment options and therapies |
| KEY MARKET DYNAMICS |
Increasing prevalence of disorders, Advances in diagnostic technologies, Rising demand for treatments, Growing awareness and education, Expanding research and development activities |
| COUNTRIES COVERED |
North America, Europe, APAC, South America, MEA |
Parathyroid Disorders Market Highlights:
Frequently Asked Questions (FAQ) :
The Global Parathyroid Disorders Market is expected to be valued at 1.99 USD Billion in 2024.
By 2035, the Global Parathyroid Disorders Market is projected to reach a value of 3.7 USD Billion.
The expected CAGR for the Global Parathyroid Disorders Market from 2025 to 2035 is 5.81 percent.
In 2024, North America is projected to dominate the market with a value of 0.9 USD Billion.
The market for Primary Hyperparathyroidism is valued at 0.9 USD Billion in 2024.
The market value for Secondary Hyperparathyroidism is projected to reach 1.1 USD Billion by 2035.
Major players include AbbVie, Eli Lilly, Zymeworks, GSK, and Novartis among others.
The expected market value for Tertiary Hyperparathyroidism is 1.0 USD Billion in 2035.
The projected market size in Europe by 2035 is expected to be 1.1 USD Billion.
Market challenges include regulatory barriers and the high cost of treatment impacting growth.
